These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 20878131)
1. Analysis of stemness gene expression and CD133 abnormal methylation in neuroblastoma cell lines. Schiapparelli P; Enguita-Germán M; Balbuena J; Rey JA; Lázcoz P; Castresana JS Oncol Rep; 2010 Nov; 24(5):1355-62. PubMed ID: 20878131 [TBL] [Abstract][Full Text] [Related]
2. Expression of CD133 and other putative stem cell markers in uveal melanoma. Thill M; Berna MJ; Grierson R; Reinhart I; Voelkel T; Piechaczek C; Galambos P; Jager MJ; Richard G; Lange C; Gehling UM Melanoma Res; 2011 Oct; 21(5):405-16. PubMed ID: 21900792 [TBL] [Abstract][Full Text] [Related]
3. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer. Kagara N; Huynh KT; Kuo C; Okano H; Sim MS; Elashoff D; Chong K; Giuliano AE; Hoon DS Am J Pathol; 2012 Jul; 181(1):257-67. PubMed ID: 22626806 [TBL] [Abstract][Full Text] [Related]
4. Latexin inhibits the proliferation of CD133+ miapaca-2 pancreatic cancer stem-like cells. Xue ZX; Zheng JH; Zheng ZQ; Cai JL; Ye XH; Wang C; Sun WJ; Zhou X; Lu MD; Li PH; Cai ZZ World J Surg Oncol; 2014 Dec; 12():404. PubMed ID: 25551472 [TBL] [Abstract][Full Text] [Related]
5. Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Friel AM; Zhang L; Curley MD; Therrien VA; Sergent PA; Belden SE; Borger DR; Mohapatra G; Zukerberg LR; Foster R; Rueda BR Reprod Biol Endocrinol; 2010 Dec; 8():147. PubMed ID: 21122138 [TBL] [Abstract][Full Text] [Related]
6. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311 [TBL] [Abstract][Full Text] [Related]
7. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Yi JM; Tsai HC; Glöckner SC; Lin S; Ohm JE; Easwaran H; James CD; Costello JF; Riggins G; Eberhart CG; Laterra J; Vescovi AL; Ahuja N; Herman JG; Schuebel KE; Baylin SB Cancer Res; 2008 Oct; 68(19):8094-103. PubMed ID: 18829568 [TBL] [Abstract][Full Text] [Related]
8. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486 [TBL] [Abstract][Full Text] [Related]
9. A distinct gene expression signature characterizes human neuroblastoma cancer stem cells. Ross RA; Walton JD; Han D; Guo HF; Cheung NK Stem Cell Res; 2015 Sep; 15(2):419-26. PubMed ID: 26342562 [TBL] [Abstract][Full Text] [Related]
10. Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks. Tabu K; Kimura T; Sasai K; Wang L; Bizen N; Nishihara H; Taga T; Tanaka S Mol Cancer; 2010 Feb; 9():39. PubMed ID: 20167130 [TBL] [Abstract][Full Text] [Related]
12. Promoter hypermethylation and loss of CD133 gene expression in colorectal cancers. Jeon YK; Kim SH; Choi SH; Kim KH; Yoo BC; Ku JL; Park JG World J Gastroenterol; 2010 Jul; 16(25):3153-60. PubMed ID: 20593500 [TBL] [Abstract][Full Text] [Related]
13. Resistance of stem-like cells from neuroblastoma cell lines to commonly used chemotherapeutic agents. Vangipuram SD; Wang ZJ; Lyman WD Pediatr Blood Cancer; 2010 Mar; 54(3):361-8. PubMed ID: 19927294 [TBL] [Abstract][Full Text] [Related]
14. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Liu G; Yuan X; Zeng Z; Tunici P; Ng H; Abdulkadir IR; Lu L; Irvin D; Black KL; Yu JS Mol Cancer; 2006 Dec; 5():67. PubMed ID: 17140455 [TBL] [Abstract][Full Text] [Related]
15. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ieta K; Tanaka F; Haraguchi N; Kita Y; Sakashita H; Mimori K; Matsumoto T; Inoue H; Kuwano H; Mori M Ann Surg Oncol; 2008 Feb; 15(2):638-48. PubMed ID: 17932721 [TBL] [Abstract][Full Text] [Related]
16. Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma. Zhang C; Xu Y; Zhao J; Fan L; Jiang G; Li R; Ling Y; Wu M; Wei L Ann Surg Oncol; 2011 Aug; 18(8):2373-80. PubMed ID: 21331808 [TBL] [Abstract][Full Text] [Related]
17. Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53. Park EK; Lee JC; Park JW; Bang SY; Yi SA; Kim BK; Park JH; Kwon SH; You JS; Nam SW; Cho EJ; Han JW Cell Death Dis; 2015 Nov; 6(11):e1964. PubMed ID: 26539911 [TBL] [Abstract][Full Text] [Related]
18. Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer. Pellacani D; Packer RJ; Frame FM; Oldridge EE; Berry PA; Labarthe MC; Stower MJ; Simms MS; Collins AT; Maitland NJ Mol Cancer; 2011 Jul; 10():94. PubMed ID: 21801380 [TBL] [Abstract][Full Text] [Related]
19. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling. Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372 [TBL] [Abstract][Full Text] [Related]
20. CD133/CD15 defines distinct cell subpopulations with differential in vitro clonogenic activity and stem cell-related gene expression profile in in vitro propagated glioblastoma multiforme-derived cell line with a PNET-like component. Kahlert UD; Bender NO; Maciaczyk D; Bogiel T; Bar EE; Eberhart CG; Nikkhah G; Maciaczyk J Folia Neuropathol; 2012; 50(4):357-68. PubMed ID: 23319191 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]